Biomarkers: what are they and how are they useful in the diagnosis and treatment of prostate cancer? On this episode of the JNM Podcast, our panel of experts explores what they call a "liquid biopsy:" using biomarkers shed by cancer cells into the bloodstream to gain vital insights about the disease and its progression, identify candidates who would benefit from certain therapies, and monitor the effectiveness of treatments. Listen now to learn more about the clinical use of biomarkers. Our h...
All content for JNM Podcast is the property of JNM and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Biomarkers: what are they and how are they useful in the diagnosis and treatment of prostate cancer? On this episode of the JNM Podcast, our panel of experts explores what they call a "liquid biopsy:" using biomarkers shed by cancer cells into the bloodstream to gain vital insights about the disease and its progression, identify candidates who would benefit from certain therapies, and monitor the effectiveness of treatments. Listen now to learn more about the clinical use of biomarkers. Our h...
Healthcare Systems Readiness: What is Limiting the RLT Scale-up?
JNM Podcast
28 minutes
1 year ago
Healthcare Systems Readiness: What is Limiting the RLT Scale-up?
Radioligand therapy (RLT) targets cancer cells with radiation while minimizing impact on surrounding healthy tissue. In this episode of JNM Podcast, our panelists discuss training, access, production capacity, and everything else that is necessary to make RLT more widely available to the patients who need it. Moderator: Ken Herrmann, MD (Universitätsmedizin, Essen, Germany). Panelists: Andrei Iagaru, MD (Stanford University Medical Center, Stanford, California), Leonhard Schaetz (Novart...
JNM Podcast
Biomarkers: what are they and how are they useful in the diagnosis and treatment of prostate cancer? On this episode of the JNM Podcast, our panel of experts explores what they call a "liquid biopsy:" using biomarkers shed by cancer cells into the bloodstream to gain vital insights about the disease and its progression, identify candidates who would benefit from certain therapies, and monitor the effectiveness of treatments. Listen now to learn more about the clinical use of biomarkers. Our h...
